An Oral GLP-1 Just Hit 89% A1c Target
A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo. The results, presented this week […]
Retatrutide Just Got Renal Data
Eli Lilly’s retatrutide — the triple-hormone receptor agonist that already made headlines in 2026 for its 2.0% A1c reduction and 16.8% body-weight loss in Type 2 diabetes — just published renal outcomes data in The New England Journal of Medicine. The ORBIT trial evaluated retatrutide in adults with Type 2 diabetes and chronic kidney disease, […]
The ADA’s Own Definition of Remission Just Hit a Wall
The American Diabetes Association’s own consensus definition of type 2 diabetes remission — HbA1c < 6.5% for at least 3 months, off all glucose-lowering medication — just turned five years old, and a growing body of 2026 evidence shows that the vast majority of patients on mainstream diabetes drugs never get close to meeting it. […]
Stanford Just Found Why GLP-1s Don’t Work for 1 in 10 People
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach […]
Lilly’s Oral GLP-1 Just Hit Its Numbers. It’s Still Not Reversal.
Eli Lilly’s oral GLP-1, orforglipron, just hit its primary endpoint in the first Phase 3 trial designed to support an FDA submission. The Lilly press release announced results from ACHIEVE-1, published in The New England Journal of Medicine, showing a 1.3%–1.6% A1c reduction and 6.8%–7.9% weight loss in adults with early Type 2 diabetes on […]
This New GLP-1 Pill Hit 89.6% A1c Goal — It Doesn’t Reverse Diabetes
The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c of 7.0% or below. Up […]
Retatrutide Matches Bariatric Surgery: What Diabetics Should Know
New long-term data from the TRIUMPH-1 extension trial — presented at the American Diabetes Association’s 2026 Scientific Sessions — shows retatrutide drove an average of 30.3% body weight loss a 104 weeks, and 65% of participants dropped below the obesity threshold entirely. That puts a weekly injectable in the same conversation as gastric bypass and […]
Lilly’s GLP-1 Pill Just Beat Oral Ozempic – It Still Won’t Reverse Diabetes
The race for the first true GLP-1 pill just ended — and it wasn’t even close. Eli Lilly‘s once-daily oral GLP-1,orforglipron, just published head-to-head Phase 3 data showing it beat oral semaglutide (the pill form ofOzempic) on both A1c and weight loss. The results dropped this week in The Lancet, with a separate Phase 3study […]
The New GLP-1 Pill Won’t Reverse Your Type 2 Diabetes
AstraZeneca just reported phase 2 results for a new once-daily GLP-1 pill called elecoglipron. The numbers look great on the surface. The question the press is not asking: does it actually reverse the disease? What the New Study Shows AstraZeneca’s elecoglipron is a once-daily oral GLP-1 receptor agonist — the first of its kind in […]
ADA 2026: New GLP-1 Drops A1c 2.2% — Now the Hard Question
The American Diabetes Association’s 86th Scientific Sessions wrapped last week in New Orleans, and the loudest headline came from Pfizer’s phase 2b VESPER-2 trial of berobenatide, a once-weekly and once-monthly GLP-1 showing a 2.2% A1c reduction and double-digit weight loss in people with Type 2 diabetes — with no plateau in sight. It’s a real […]